OBJECTIVES: This study sought to examine the association between baseline beta-blocker (BB) dose and outcomes in the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. BACKGROUND:Beta-blockers reduce morbidity and mortality in chronic heart failure (HF) patients with reduced ejection fraction, but it is unclear whether titrating to higher BB doses improves outcomes in this setting. METHODS: The HF-ACTION trial was a randomized, multicenter trial enrolling 2,331 ambulatory HF patients with systolic dysfunction (New York Heart Association functional class II to IV, left ventricular ejection fraction <0.35) randomized toexercise training versus usual care, with median follow-up of 2.5 years. The BB dose at baseline was standardized with carvedilol equivalents and analyzed as a continuous variable and by discrete dose groups. The relationship between BB dose and the primary endpoint of all-cause mortality or all-cause hospitalization and other cardiovascular secondary endpoints was determined before and after adjustment for variables significantly associated with outcomes in the HF-ACTION cohort. RESULTS: Ninety-five percent of patients were receiving a BB. There was a significant inverse relationship between BB dose and all-cause death or hospitalization but not other cardiovascular endpoints after adjustment for other predictors of outcome, with a linear benefit up to the 50-mg daily dose. There was a significant association between BB dose and change in peak VO(2) at 3 months. There was no increase in bradycardia with higher doses of BB. CONCLUSIONS: There was a significant inverse relationship between BB dose and the endpoint of all-cause death or all-cause hospitalization in this well-treated HF cohort with systolic dysfunction, supporting recommendations that titrating doses up to 50 mg/day might confer a benefit in such patients. (Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437).
RCT Entities:
OBJECTIVES: This study sought to examine the association between baseline beta-blocker (BB) dose and outcomes in the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. BACKGROUND: Beta-blockers reduce morbidity and mortality in chronic heart failure (HF) patients with reduced ejection fraction, but it is unclear whether titrating to higher BB doses improves outcomes in this setting. METHODS: The HF-ACTION trial was a randomized, multicenter trial enrolling 2,331 ambulatory HF patients with systolic dysfunction (New York Heart Association functional class II to IV, left ventricular ejection fraction <0.35) randomized to exercise training versus usual care, with median follow-up of 2.5 years. The BB dose at baseline was standardized with carvedilol equivalents and analyzed as a continuous variable and by discrete dose groups. The relationship between BB dose and the primary endpoint of all-cause mortality or all-cause hospitalization and other cardiovascular secondary endpoints was determined before and after adjustment for variables significantly associated with outcomes in the HF-ACTION cohort. RESULTS: Ninety-five percent of patients were receiving a BB. There was a significant inverse relationship between BB dose and all-cause death or hospitalization but not other cardiovascular endpoints after adjustment for other predictors of outcome, with a linear benefit up to the 50-mg daily dose. There was a significant association between BB dose and change in peak VO(2) at 3 months. There was no increase in bradycardia with higher doses of BB. CONCLUSIONS: There was a significant inverse relationship between BB dose and the endpoint of all-cause death or all-cause hospitalization in this well-treated HF cohort with systolic dysfunction, supporting recommendations that titrating doses up to 50 mg/day might confer a benefit in such patients. (Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437).
Authors: Marco Metra; Christian Torp-Pedersen; Karl Swedberg; John G F Cleland; Andrea Di Lenarda; Michel Komajda; Willem J Remme; Beatrix Lutiger; Armin Scherhag; Mary Ann Lukas; Andrew Charlesworth; Philip A Poole-Wilson Journal: Eur Heart J Date: 2005-07-21 Impact factor: 29.983
Authors: M Packer; P A Poole-Wilson; P W Armstrong; J G Cleland; J D Horowitz; B M Massie; L Rydén; K Thygesen; B F Uretsky Journal: Circulation Date: 1999-12-07 Impact factor: 29.690
Authors: M R Bristow; E M Gilbert; W T Abraham; K F Adams; M B Fowler; R E Hershberger; S H Kubo; K A Narahara; H Ingersoll; S Krueger; S Young; N Shusterman Journal: Circulation Date: 1996-12-01 Impact factor: 29.690
Authors: John Wikstrand; Ake Hjalmarson; Finn Waagstein; Björn Fagerberg; Sidney Goldstein; John Kjekshus; Hans Wedel Journal: J Am Coll Cardiol Date: 2002-08-07 Impact factor: 24.094
Authors: Marvin A Konstam; James D Neaton; Kenneth Dickstein; Helmut Drexler; Michel Komajda; Felipe A Martinez; Gunter A J Riegger; William Malbecq; Ronald D Smith; Soneil Guptha; Philip A Poole-Wilson Journal: Lancet Date: 2009-11-16 Impact factor: 79.321
Authors: H Krum; J D Sackner-Bernstein; R L Goldsmith; M L Kukin; B Schwartz; J Penn; N Medina; M Yushak; E Horn; S D Katz Journal: Circulation Date: 1995-09-15 Impact factor: 29.690
Authors: Gregg C Fonarow; Clyde W Yancy; Nancy M Albert; Anne B Curtis; Wendy Gattis Stough; Mihai Gheorghiade; J Thomas Heywood; Mark L McBride; Mandeep R Mehra; Christopher M O'Connor; Dwight Reynolds; Mary Norine Walsh Journal: Circ Heart Fail Date: 2008-05-28 Impact factor: 8.790
Authors: Huiyin Tu; Jinxu Liu; Dongze Zhang; Hong Zheng; Kaushik P Patel; Kurtis G Cornish; Wei-Zhong Wang; Robert L Muelleman; Yu-Long Li Journal: Am J Physiol Cell Physiol Date: 2013-09-11 Impact factor: 4.249
Authors: Poghni A Peri-Okonny; Xiaojuan Mi; Yevgeniy Khariton; Krishna K Patel; Laine Thomas; Gregg C Fonarow; Puza P Sharma; Carol I Duffy; Nancy M Albert; Javed Butler; Adrian F Hernandez; Kevin McCague; Fredonia B Williams; Adam D DeVore; J Herbert Patterson; John A Spertus Journal: JACC Heart Fail Date: 2019-02-06 Impact factor: 12.035
Authors: Sanjay Verma; Edward L Peterson; Bin Liu; Hani N Sabbah; L Keoki Williams; David E Lanfear Journal: Eur J Clin Pharmacol Date: 2020-05-22 Impact factor: 2.953
Authors: Mona Fiuzat; Justin Ezekowitz; Wendimagegn Alemayehu; Cynthia M Westerhout; Marco Sbolli; Dario Cani; David J Whellan; Tariq Ahmad; Kirkwood Adams; Ileana L Piña; Chetan B Patel; Kevin J Anstrom; Lawton S Cooper; Daniel Mark; Eric S Leifer; G Michael Felker; James L Januzzi; Christopher M O'Connor Journal: JAMA Cardiol Date: 2020-07-01 Impact factor: 14.676
Authors: Mostafa El-Refai; Edward L Peterson; Karen Wells; Tanmay Swadia; Hani N Sabbah; John A Spertus; L Keoki Williams; David E Lanfear Journal: J Card Fail Date: 2013-02 Impact factor: 5.712
Authors: Robert J Mentz; Phillip J Schulte; Jerome L Fleg; Mona Fiuzat; William E Kraus; Ileana L Piña; Steven J Keteyian; Dalane W Kitzman; David J Whellan; Stephen J Ellis; Christopher M O'Connor Journal: Am Heart J Date: 2012-11-28 Impact factor: 4.749